- ASSISTANT CLINICAL PROFESSOR Psychiatry
B.A., Cornell University
M.D., SUNY Upstate Medical University
Dr. Garakani is a former Attending Psychiatrist at Mount Sinai Hospital. He currently is on the full-time staff at Silver Hill Hospital in New Canaan, CT. He is certified by the American Board of Psychiatry and Neurology in Psychiatry and Forensic Psychiatry. He received his B.A. in Classics (Latin), cum laude, with Distinction in All Subjects, from Cornell University, and his M.D. from the SUNY Upstate Medical University in Syracuse, NY, where he won the AMA Rock Sleyster Scholarship. He completed his residency at the Mount Sinai Medical Center and a research fellowship at the Mood and Anxiety Disorders Program at the Mount Sinai School of Medicine. Dr. Garakani also completed a fellowship in Forensic Psychiatry at New York University Medical Center. He has won several awards including the American Psychiatric Association (APA)/Lilly Resident Research Award, APA – NY County District Branch Resident Research Award, and travel awards from the Anxiety Disorders Association of America and Society of Biological Psychiatry. He also was an APA/GlaxoSmithKline Fellow and a Fellow of the Group of the Advancement of Psychiatry. He has participated in NIMH-funded research and is first or co-author on over 25 peer-reviewed original research papers, review papers and book chapters. He teaches classes to Mount Sinai residents on psychopharmacology and forensic psychiatry and is a supervisor to psychiatry residents and medical students. He also is on the Executive Council of the APA NY County District Branch and a Fellow of the APA and NY Academy of Medicine.
Goldberg JF, Garakani A, Ackerman SH. Clinician- versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance abuse. J Clin Psychiatry 2012; 73(12): 1525–1530.
Krystal JH, Mathew SJ, D’Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor glutamate receptor agonists and antagonists. CNS Drugs 2010; 24(8): 669-693.
Garakani A, Buchsbaum MS, Newmark RE, Goodman C, Aaronson CJ, Martinez JM, Torosjan Y, Chu K, Gorman JM. The effect of doxapram on brain imaging in patients with panic disorder. Eur Neuropsychopharmacol 2007; 17(10): 672-686.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatments. Mt Sinai J Med 2006; 73(7): 941-949.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Garakani did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
128 East Avenue
Norwalk, CT 06851